Both STAG2 mutations and the expression of EWS-FLI1 fusion are frequently encountered in Ewing’s sarcoma and are likely an explanation to why this tumor type demonstrates an overall greater sensitivity to PARP inhibition compared to other pediatric tumor types. This evidence concerns the gene EWSR1 and Ewing sarcoma.